The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Granules now have a total of 53 ANDA approvals from USFDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
